Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) FCF Margin (2016 - 2025)

Zevra Therapeutics' FCF Margin history spans 9 years, with the latest figure at 16.24% for Q4 2025.

  • For Q4 2025, FCF Margin rose 15131.0% year-over-year to 16.24%; the TTM value through Dec 2025 reached 2.28%, up 29322.0%, while the annual FY2025 figure was 2.28%, 29291.0% up from the prior year.
  • FCF Margin reached 16.24% in Q4 2025 per ZVRA's latest filing, up from 15.92% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 138.37% in Q2 2021 to a low of 5386.99% in Q3 2022.
  • Average FCF Margin over 5 years is 399.34%, with a median of 114.33% recorded in 2023.
  • Peak YoY movement for FCF Margin: tumbled -524485bps in 2022, then skyrocketed 522119bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 33.5% in 2021, then crashed by -34bps to 45.01% in 2022, then tumbled by -179bps to 125.62% in 2023, then dropped by -8bps to 135.07% in 2024, then skyrocketed by 112bps to 16.24% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's FCF Margin are 16.24% (Q4 2025), 15.92% (Q3 2025), and 14.73% (Q2 2025).